The burden of invasive fungal infections associated with opportunistic fungal pathogens is a persistent challenge, particularly among people with advanced HIV disease. In October, 2022, WHO published the Fungal Priority Pathogens List (FPPL)—the first global effort to systematically prioritise fungal pathogens. Of the 19 pathogens in the WHO FPPL, four opportunistic pathogens in particular cause invasive diseases in people living with HIV: Cryptococcus neoformans, Histoplasma spp., Pneumocystis jirovecii, and Talaromyces marneffei. These four fungal pathogens are major causes of illness and death in people with advanced HIV and overwhelmingly affect those in low-income and middle-income countries. Access to diagnostics, improved surveillance, targeted support for innovation, and an enhanced public health focus on these diseases are needed in the effort to reduce HIV-associated deaths.

Introduction

The burden of disease associated with invasive fungal infections is rising due to growth of immunocompromised populations (including people with advanced HIV), new viral comorbidities (eg, SARS-CoV-2 and influenza), and improved diagnostic tests allowing easier identification. However, there is a paucity of data on the distribution of fungal disease globally, with no systematic assessment or reporting of infections. Therefore, fungal infections receive insufficient recognition from national and global agencies, and their prevention, control, and treatment are inadequately funded.

In October, 2022, WHO released the Fungal Priority Pathogens List (FPPL)—the first global effort to systematically prioritise fungal pathogens. The FPPL was developed after expert review of both the public health importance and diagnostic and therapeutic development needs associated with each pathogen.1 The prioritisation process was led by WHO in consultation with a group of experts in fungal diseases and was informed by a series of systematic reviews, which provided updated estimates of the disease burden and effect of fungal infections on human health. The focus was on pathogens that cause invasive fungal diseases for which there is insufficient access to effective, rapid, and early diagnosis and treatment, and the efficacy of existing preventive and therapeutic strategies are threatened by the rise of antifungal resistance. 19 fungal pathogens were assessed against ten criteria: mortality, annual incidence, global distribution, changes in incidence and prevalence patterns in the last 10 years, inpatient care, complications from disease, antifungal resistance, preventability, and access to diagnostic tests and evidence-based treatments.

Of the 19 pathogens in the WHO FPPL, four opportunistic pathogens cause invasive diseases in people living with HIV: Cryptococcus neoformans, Histoplasma spp., Pneumocystis jirovecii, and Talaromyces marneffei (previously known as Penicillium marneffei). In this Viewpoint we summarise gaps in prevention, diagnosis, and treatment of infections caused by these priority pathogens and opportunities for innovation and improved access to diagnostics and therapeutics (figure).

Cryptococcus spp

Cryptococcal disease is one of the most common opportunistic infections in people living with advanced HIV and is a major contributor to morbidity and mortality. The dominant pathogenic species is Cryptococcus neoformans, which is a key priority pathogen ranked number 1 according to the WHO FPPL. C. gattii infections are less common and were ranked as medium priority; however, the resulting disease in people with advanced HIV is indistinguishable from those caused by C. neoformans.2

Globally, cryptococcosis accounts for one in five AIDS-related deaths. An updated review3 of the burden of cryptococcal disease estimated that there were 179,000 cases of cryptococcal infection (antigenaemia) and 152,000 cases of cryptococcal meningitis globally in 2020, which resulted in 112,000 cryptococcal-related deaths that year. Despite widespread use of antiretroviral treatment, incidence of cryptococcosis remains high. A study3 from sub-Saharan Africa found that over half of individuals diagnosed with the first episode of cryptococcal meningitis were antiretroviral drug experienced. WHO recommends screening for cryptococcal antigenaemia in adults and adolescents with a CD4 cell count of less than 200 cells per µL.4 Accurate and affordable point-of-care cryptococcal antigen screening with lateral flow assays helps determine the need for pre-emptive antifungal therapy among those with antigenaemia; this intervention can reduce the incidence of meningitis and cryptococcosis-related mortality.5 Implementation of this life-saving recommendation is hampered by uneven access to this screening tool globally and by inadequate follow-up of individuals with antigenaemia for timely initiation and continuation of pre-emptive fluconazole.

Advances in the management of cryptococcal meningitis have simplified treatment for all, including for people living with HIV. Guidelines released by WHO in 2022 strongly recommend a single high dose of liposomal amphotericin B, followed by 2 weeks of fluconazole as the preferred induction treatment.6 The regimen containing a single dose of liposomal amphotericin B has a lower risk of side-effects than longer courses, reducing toxicity monitoring needs.
which might allow for faster hospital discharge.\textsuperscript{8}\textsuperscript{a} This regimen is only marginally more expensive than the regimen previously recommended by WHO (1-week daily doses of amphotericin B deoxycholate), which was also associated with serious off-target toxic effects (including nephrotoxicity and anaemia).\textsuperscript{16}

The persistently high mortality from cryptococcal meningitis among people living with HIV is partly because of delayed diagnosis, which results from the non-specific nature the initial symptoms (ie, headache), poor access to rapid diagnostic assays, and the need for lumbar puncture to establish the diagnosis and then to manage raised intracranial pressure. Access to liposomal amphotericin B and companion drugs is another major challenge,\textsuperscript{11} due to multiple market failures, including high cost and limited national drug registration (partly as a result of small capacity and poor coordination of drug regulatory authorities in many countries), low demand from countries, poor demand forecasting estimates, and few suppliers. More clinical experience is needed with the single high-dose liposomal amphotericin B regimen in countries where this treatment is available; currently the combination of liposomal amphotericin B plus fluocytosine is usually still given for a 2-week induction period in countries with sufficient resources.\textsuperscript{15}

\textbf{Histoplasma spp}

Histoplasmosis is another global opportunistic infection, and one of the most common among people with advanced HIV disease in Latin America. Histoplasma spp lives as a mould in the environment. Most people who inhale the spores of Histoplasma spp are asymptomatic or develop symptoms not requiring medical attention. However, people living with HIV and other immunocompromised patients, such as people with cancer and organ transplant recipients, can develop severe disseminated forms of histoplasmosis, and mortality can be high. Histoplasma spp are ranked as a high priority in the WHO FPPL.

The most common clinical presentation of histoplasmosis in people living with HIV is progressive disseminated disease. Symptoms are non-specific and often indistinguishable from other infectious diseases (eg, disseminated tuberculosis), which complicates management. In 2020, WHO and the Pan American Health Organization released standard guidelines for the diagnosis, treatment, and management of disseminated histoplasmosis in people living with HIV.\textsuperscript{11}

Histoplasmosis is highly endemic in some parts of the Americas, where it causes 15 600 new infections and 4500 deaths among people living with HIV each year. Infections are also reported across Asia and Africa, but the disease burden in these regions is unknown, in part due to inadequate diagnostic capacity and surveillance. Access to traditional diagnostic methods—cell culture and histopathology—are restricted by the need for complex laboratory infrastructure, trained staff, and long turnaround times affecting treatment outcomes. Antigen detection methods have improved diagnostic accuracy, but these technologies are not yet widely available or optimised for accurate diagnosis in the lateral flow assay format. There is generally a low clinical index of suspicion, which should be improved through training of health-care providers.

Access to appropriate antifungal therapies, including liposomal amphotericin B and itraconazole, is inadequate. Fluconazole has inferior therapeutic efficacy compared with itraconazole, and development of fluconazole resistance\textsuperscript{20} is another important limitation of this drug. Licensing of liposomal amphotericin B and itraconazole is encouraged so that skilled clinicians can use them where most needed. A phase 2 multicentre randomised trial\textsuperscript{19} found that a single high dose of liposomal amphotericin B is safe, which indicates an opportunity to shorten and simplify treatment and this is under evaluation in a phase 3 trial.

\textbf{P jirovecci}

Pneumocystis pneumonia is a leading cause of mortality in hospitalised adults and children living with HIV. \textit{P jirovecci} is transmitted from person to person through the air. The main ways to prevent and treat this infection among people living with HIV, according to WHO and most national guidelines, are use of co-trimoxazole and rapid early initiation of antiretroviral therapy.\textsuperscript{4}

Diagnosis of pneumocystis pneumonia has traditionally relied upon clinical symptoms, radiographic findings, and microscopy because \textit{P jirovecci} cannot be cultured. Non-culture-based diagnostics on sputum or bronchoalveolar lavage, such as PCR, have entered clinical use, but there is often inadequate infrastructure for these assays in resource-limited settings.\textsuperscript{7} A review of published studies found a disease prevalence of 19% among symptomatic adults with HIV in Africa, with little change despite increased access to prophylaxis regimens.\textsuperscript{16}

\textit{P jirovecci} was ranked as medium priority in the WHO FPPL, considering the high availability and

![Figure: Prevention, diagnosis, and treatment of HIV-associated infections caused by priority fungal pathogens in low-income and middle-income countries](http://www.thelancet.com/hiv)\textsuperscript{a} Intervention recommended by WHO guidelines.
affordability of prophylaxis and treatment, and moderate availability of conventional diagnostics. Nevertheless, accurate and cost-effective point-of-care diagnostic options for *P. jirovecii* infections are needed. Antigen testing, which is effective for diagnosis of other fungal infections, is a promising approach in development; several other diagnostic techniques show promise in research settings, but their applicability in resource-limited settings remains unclear.7 Existing antifungal therapies are associated with important toxic effects, drug resistance, and access challenges, and a number of alternative therapeutic options to overcome these challenges can be considered.9

**T marneffei**

Talaromycosis is one of the most common invasive fungal diseases in people with advanced HIV disease in southeast Asia. *T. marneffei* is endemic in higher altitude regions of southeast Asia and parts of China, India, and Indonesia, with a reported prevalence of more than 10% in some regions.8 The fungus is found in the environment and causes lung disease with multiorgan haematogenous dissemination in humans after inhalation of spores. The clinical manifestations commonly include skin lesions, which can be stigmatising for people who live in endemic areas. Like most fungal infections acquired from the environment, there is no human-to-human transmission.

Invasive talaromycosis affects people living with HIV and other immunocompromised patients, and in endemic areas it can be responsible for up to 15% of HIV-related hospital admissions. Talaromycosis mortality rates of up to 30% have been reported, which can be reduced with amphotericin-B induction therapy.21-23 Diagnosis is presumptively based on microscopy; although PCR-based assays are available, their sensitivity is low. Antigen tests, including rapid point-of-care tests, are in development, and if sufficiently accurate, they could be used for screening of early talaromycosis in patients with advanced HIV disease.26 Given its restricted geographical distribution, *T. marneffei* is considered to be of medium priority by the WHO FPPL.

**Other invasive fungal pathogens**

People with advanced HIV disease are at risk of illness and death from a wide range of infectious diseases. *Candida* spp, *Paracoccidioides* spp, *Coccidioides* spp, and *Aspergillus fumigatus* most commonly cause severe disease in other patient populations, but they are also important opportunistic pathogens in people living with HIV.27 Severe disease in people living with HIV caused by most of the pathogens on the FPPL is frequently reported. In Brazil, mortality of 73% was reported in a retrospective review of outcomes of 11 severely immunocompromised people with HIV and invasive aspergillosis.27 In South Africa, people with HIV admitted to hospital with candidaemia had almost twice the risk of mortality compared with HIV-seronegative patients.27

**WHO FPPL and priority areas for action**

The four fungal diseases highlighted in this Viewpoint are among the major causes of infections and death in people with advanced HIV, and overwhelmingly affect people in low-income and middle-income countries. Unfortunately, there is little data regarding the complications and sequelae of infections with these and other fungal pathogens. Also, clinical questions on including optimal diagnostic approach, preventive and treatment regimens, and duration of inpatient care remain unanswered. Many laboratories worldwide do not have the expertise of specialised mycology laboratories, where microscopic examination, cell culture, and morphological identification have long been the primary methods for diagnosis of fungal infections. A survey of diagnostic capacity for invasive fungal pathogens across 48 countries in Africa between 2020 and 2022 found an insufficient number of diagnostic tools leading to under-reporting of disease burden, which in turn leads to insufficient resource allocation for diagnosis and treatment.28 Similarly, a 2018 survey of mycological diagnostic and therapeutic capabilities in 24 countries in Latin America and the Caribbean concluded that there is an urgent need to improve diagnostic capacity and access to treatment. A 2022 survey across 40 countries in the Asia-Pacific region found that resources for diagnosing and access to treatment for invasive fungal pathogens varied across the region; the survey concluded that regional cooperation could help overcome multiple limitations.

There is a need to use new point-of-care diagnostics at all levels of HIV care as affordable and accurate diagnostic tests support earlier initiation of therapeutic strategies leading to improved treatment outcomes. Improvement of surveillance, targeted support for innovation, and enhanced public health interventions are some of the other priorities for reducing HIV-associated illness and death.

Progress in laboratory surveillance of *C neoformans*, *Histoplasma* spp, *P. jirovecii*, and *T. marneffei* infections will depend on access to laboratories with mycology diagnostic capacity, particularly in settings with a high HIV prevalence; development and adoption of cheap, accurate lateral flow assays in all settings should be the goal. Some lateral flow assays are in development, but cryptococcal antigen assays are commercially available through several manufacturers (although their performance varies). Mycology laboratories can be added to health-care facilities, where people living with HIV receive care, are diagnosed, and surveillance programmes are already in place. This approach takes advantage of existing health-care infrastructure to enhance the diagnosis and treatment of opportunistic fungal infections. Efforts have been made (in particular, the development of alternative diagnostic methods) to overcome the challenges that have prevented diagnosis of life-threatening invasive fungal diseases due to poor access to mycology laboratories. Precedence
for this approach was established with another slowly replicating microorganism—Mycobacterium tuberculosis—
the handling of which also requires biosafety level 3
facilities. Lateral flow assay devices and commercial
PCR techniques have made diagnostic procedures
accessible to laboratories without specialised tuberculosis
or mycology expertise. In areas where microbiology
facilities are available, it is essential to use techniques
that provide rapid results. Virologists routinely use PCR,
lateral flow assays, ELISA sequencing, and other
techniques; they possess the necessary technical expertise
to extend diagnostic capabilities to other microbiology
specialties, including mycology.

Linkage of laboratory and clinical data can help to
estimate the burden of fungal infections and antifungal
resistance in people living with HIV. Such integrated
data are scarce, especially in low-income settings.
Improved clinical screening of populations at risk of
fungal infections will depend on the level of training of
the health-care worker and will be supported by
community knowledge and education about clinical
presentations and risk factors for these infections among
people living with HIV. Affordable access to diagnostic
tools at the point of care is essential for optimal patient
care and screening of at-risk populations for acquisition
of accurate surveillance data. Commitment made by
donor institutions, implementing partners, and
governments in individual countries is needed to
facilitate robust data collection and reporting.

Given the high mortality rates associated with invasive
fungal diseases in people with HIV treated with many of
the available therapies, novel antifungal agents
and improved regimens are urgently needed. Further
research and innovation should optimise the way
current antifungals and diagnostics are used, such as
strategies to improve availability of therapeutic antifungal
monitoring and to optimise combination therapies that
prevent drug resistance emergence and increase efficacy.
Investment in the development of novel antifungals
and affordable diagnostic tools for invasive fungal pathogens
affecting people living with HIV is essential and can be
leveraged to diagnose and treat these mycoses in other
growing immunosuppressed patient populations.

Finally, education on the importance of fungal patho-
gens among people living with HIV should be expanded.
Health-care workers in many settings are unfamiliar
with fungal infections, resulting in low clinical
suspicion, misdiagnosis, incorrect or delayed treatment,
and poor outcomes. Fungal infections need to be
included in the early and ongoing medical and public
health training, and specifically integrated into HIV
care training.19

Advanced HIV disease is receiving increased attention
from major donors including the Global Fund to Fight
AIDS, Tuberculosis and Malaria, the US Presidents’
Emergency Plan for AIDS Relief, and UNITAID. Important
initiatives have been launched in the last 5 years,
including a drive to End Cryptococcal Deaths in HIV by
2030.20 There is a need to increase the recognition of and
focus on fungal diseases, with the goal to support
development and to scale up access to preventives,
diagnostics, and treatments for infections caused by
these pathogens. Early and effective therapies can make a
difference in fungal infection outcome, and improved
diagnostics and treatments are needed.

Contributors

HS and NF conceptualised this Viewpoint. NF wrote the first draft. All
authors provided scientific input, reviewed and edited the manuscript,
and approved the final version of the Viewpoint.

Declaration of interests

NPG has received grants from National Institute for Health Research,
US Centers for Disease Control and Prevention, US National Institutes
of Health, UK Medical Research Council, the Bill & Melinda Gates
Foundation, and the National Health Laboratory Service Research
Trust. AA-I has received honoraria from Pfizer and Gilead for
educational lectures; and is the chair of WHO’s technical expert group
for the development of the final priority pathogens list, chair of the
fungi infection study group for the European Society of Clinical
Microbiology and Infectious Diseases, president of the Spanish Society
for Mycology, director of Latin American Programs for Global Action
Fund for Fungal Infections, and a member of the scientific advisory
board of the Joint Programming Initiative on Antimicrobial Resistance.
HS has received grants from the Governments of Austria and
Germany, the European Union Health Emergency Preparedness and
Response, the US Centers for Disease Control and Prevention, and the
Golden Key International Honour Society. JP has received grants from
the US National Institutes of Health; and is the president of
International Society for Human and Animal Mycology and the past
president of the Mycoses Study Group Education & Research
Consortium. AC has received personal and institutional payments from
ACHE, Eurofarma, Gilead, Mundipharma, Knight-Biotoscana, and
Pfizer; and has obtained financial support for travel from
Knight-Biotoscana. All other authors declare no competing interests.

Acknowledgments

We thank all members of the WHO Global Coordination and
Partnership Team, the WHO Advisory Group on the Fungal Priority
Pathogens List, the commissioned technical group, and all external
global partners. We thank the Bill & Melinda Gates Foundation for
funding this Viewpoint, and Shihab S Joi for generating the figure.

References

1 WHO. Fungal Priority Pathogens List to guide research,
development, and public health action. 2022. https://www.who.int/
infection: characteristics and epidemiology of cases identified in
a South African province with high HIV seroprevalence, 2002–04.
of HIV-associated cryptococcal meningitis: an updated analysis.
4 Rajasingham R, Govender NP, Jordan A, et al. The global burden of
HIV-associated cryptococcal meningitis in adults in 2020: a modelling
5 Kalita N, Ellis J, Kanyama C, et al. Short-term mortality outcomes
of HIV-associated cryptococcal meningitis in antiretroviral therapy-
naïve and therapy-experienced patients in sub-Saharan Africa.
Open Forum Infect Dis 2021; 8: ofab397.
6 WHO. Guidelines for diagnosing, preventing and managing
cryptococcal disease among adults, adolescents and children living
with HIV, 2022. https://www.who.int/publications/i/item/9789240052378
screening and community-based early adherence support in people
with advanced HIV infection starting antiretroviral therapy in
Tanzania and Zambia: an open-label, randomised controlled trial.


Copyright © 2023 World Health Organization. Published by Elsevier Ltd. All rights reserved.